Hematopathologic findings in chronic idiopathic myelofibrosis

被引:48
作者
Thiele, J [1 ]
Kvasnicka, HM [1 ]
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
关键词
D O I
10.1053/j.seminoncol.2005.04.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Until now scant knowledge was available about the dynamics of chronic idiopathic myelofibrosis (CIMF). However, follow-up studies are in keeping with a stepwise evolution starting with a prefibrotic (hypercellular) phase that progressively transforms into the classical fibro-osteosclerotic endstage with myeloid metaplasia. Prefibrotic CIMF is characterized by a granulocytic and megakaryocytic myeloproliferation lacking an increase in reticulin. Most conspicuous are abnormalities of megakaryopoiesis with regard to their histotopography and maturation. There is a more than 65% probability of progression from an early to advanced CIMF accompanied by increasing anemia, splenomegaly, and leuko-erythroblastosis. A significant relationship is recognizable among frequency, tortuosity, and luminal dilation of the microvessels and the extent of myelofibrosis. Quantity of CD34+ progenitor cells in the bone marrow (BM) reveals a close association with advancement of disease (fibrosis, splenomegaly, anemia, peripheral blasts) and therefore prognosis. Cell kinetic studies show increased proliferation associated with a higher rate of apoptosis in initial (hypercellular) stages, as well as a reduced endoreduplicative activity of megakaryopoiesis and a blocked synthesis phase of the erythroid precursors. It is noteworthy that prefibrotic and early CIMF often present with a marked thrombocytosis mimicking essential thrombocythemia. Regarding prognosis, early CIMF is associated with a significantly more favorable survival than advanced stages. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:380 / 394
页数:15
相关论文
共 139 条
[21]   Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens [J].
Buhr, T ;
Büsche, G ;
Choritz, H ;
Länger, F ;
Kreipe, H .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (01) :152-158
[22]   Thalidomide in agnogenic and secondary myelofibrosis [J].
Canepa, L ;
Ballerini, F ;
Varaldo, R ;
Quintino, S ;
Reni, L ;
Clavio, M ;
Miglino, M ;
Pierri, I ;
Gobbi, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) :313-315
[23]  
Cervantes F, 1998, EUR J HAEMATOL, V60, P101
[24]   Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups [J].
Cervantes, F ;
Barosi, G ;
Demory, JL ;
Reilly, J ;
Guarnone, R ;
Dupriez, B ;
Pereira, A ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :684-690
[25]   Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis [J].
Cervantes, F ;
Pereira, A ;
Esteve, J ;
Rafel, M ;
Cobo, F ;
Rozman, C ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) :635-640
[26]  
CERVANTES F, 1991, ACTA HAEMATOL-BASEL, V85, P124
[27]   INCREASED VASCULARITY OF BONE-MARROW IN MYELOFIBROSIS [J].
CHARBORD, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 62 (03) :595-596
[28]   INCREASE IN CIRCULATING STEM-CELLS IN PATIENTS WITH MYELOFIBROSIS [J].
CHERVENICK, PA .
BLOOD, 1973, 41 (01) :67-71
[29]   INCREASED GRANULOCYTIC, ERYTHROCYTIC, AND MEGAKARYOCYTIC PROGENITORS IN MYELOFIBROSIS WITH MYELOID METAPLASIA [J].
CHIKKAPPA, G ;
CARSTEN, AL ;
CHANANA, AD ;
CHANDRA, P ;
CRONKITE, EP .
AMERICAN JOURNAL OF HEMATOLOGY, 1978, 4 (02) :121-131
[30]   Beyond chronic myelogenous leukemia - Potential role for imatinib in Philadelphia-negative myeloproliferative disorders [J].
Cortes, J ;
Kantarjian, H .
CANCER, 2004, 100 (10) :2064-2078